Senesco Technologies to Present at 6th Annual Rodman & Renshaw Global Healthcare Conference
May 10 2010 - 8:24AM
Business Wire
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE
Amex:SNT) today announced that the Company will be presenting at
the 6th Annual Rodman & Renshaw Global Healthcare Conference
being held at the Grosvenor House Hotel in London, England from May
16th – 18th, 2010. Harlan Waksal, M.D., Senesco’s Executive
Chairman, will deliver the Company’s corporate presentation on
Monday, May 17th, at 11:30 AM Greenwich Mean Time (6:30 AM Eastern
Daylight Time.)
Dr. Waksal will be available for one-on-one meetings with
investors participating in the Rodman & Renshaw Global
Healthcare Conference. For those who would like to schedule an
appointment with Senesco management, please contact Anne Marie
Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777
or at afields@lhai.com or contact your Rodman & Renshaw
representative.
The presentation will be webcast live at
http://wsw.com/webcast/rrshq17/snt and at the Investor Relations
section of the Company’s website at www.senesco.com where it will
also be archived for 90 days.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company,
headquartered in New Brunswick, NJ. Senesco has initiated
preclinical research to trigger or delay cell death in mammals
(apoptosis) to determine if the technology is applicable in human
medicine. Accelerating apoptosis may have applications to
development of cancer treatments. Delaying apoptosis may have
applications to certain diseases inflammatory and ischemic
diseases. Senesco takes its name from the scientific term for the
aging of plant cells: senescence. Delaying cell breakdown in plants
extends freshness after harvesting, while increasing crop yields,
plant size and resistance to environmental stress. The Company
believes that its technology can be used to develop superior
strains of crops without any modification other than delaying
natural plant senescence. Senesco has partnered with leading-edge
companies engaged in agricultural biotechnology and earns research
and development fees for applying its gene-regulating platform
technology to enhance its partners’ products.
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and joint ventures; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; success of the Company’s
preliminary studies and preclinical research; competition and the
timing of projects and trends in future operating performance, the
Company’s ability to meet its funding milestones under its
financing transaction, the Company’s ability to continue to comply
with the continued listing standards of the AMEX, as well as other
factors expressed from time to time in the Company’s periodic
filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with the
Company’s periodic filings with the SEC. The forward-looking
statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Senesco (AMEX:SNT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Senesco Technologies (American Stock Exchange): 0 recent articles
More Senesco Technologies, Inc. News Articles